3-Hydrazino-6-(4-methyl-piperazino)-pyridazin | 17259-79-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-Hydrazino-6-(4-methyl-piperazino)-pyridazin
• 英文别名: 3-hydrazino-6-(4-methyl-piperazin-1-yl)-pyridazine；3-Hydrazino-6-(4-methyl-1-piperazinyl)-pyridazine；[6-(4-methylpiperazin-1-yl)pyridazin-3-yl]hydrazine
• CAS: 17259-79-9
• 化学式: C₉H₁₆N₆
• 分子量: 208.266
• InChiKey: FPAOMVHSUQKCIG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  70.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-Hydrazino-6-(4-methyl-piperazino)-pyridazin 、 乙酰乙酸叔丁酯 以59%的产率得到
  参考文献：
  名称：

  SZILACYI, G.;KASZIREINER, E.;MATYUS, P.;KOSARY, J.;CZAKO, K.;CSEH, G.;HUS+, EUR. J. MED. CHEM., 1984, 19, N 2, 111-117

  摘要：

  DOI：

文献信息

• N-Pyrrolyl-pyridazineamines and their use as antihypertensive agents
  申请人：Gruppo Lepetit S.p.A.

  公开号：US04247551A1

  公开（公告）日：1981-01-27

  New-pyrrolyl-3-pyridazineamines having a further aminic substituent in the position 6. The compounds are useful as antihypertensive agents and may be prepared from 6-amino substituted-3-hydrazino pyridazines and .beta.-dicarbonyl compounds. The use of the novel compounds as antihypertensives and compositions containing the novel compounds as active ingredients are also claimed.

  新的吡咯基-3-吡啶嗪胺类化合物，在位置6上进一步具有氨基取代基。这些化合物可用作降压药物，并可从6-氨基取代-3-肼基吡啶嗪和β-二羰基化合物制备。本发明还声明了将新化合物用作降压药物以及含有新化合物作为活性成分的组合物的用途。
• 6-Amino substituted N-pyrrolyl-3-pyridazine amines, their preparation, and pharmaceutically antihypertensive compositions containing them
  申请人：GRUPPO LEPETIT S.P.A.

  公开号：EP0009655A1

  公开（公告）日：1980-04-16

  New N-pyrrolyl-3-pyridazine-amines having a further aminic substituent in the 6 position of the formula (I), wherein R, R1, R2 and R3 are hydrogen or lower alkyl, R4 is e.g hydrogen or lower alkyl, R5 and R6 are e.g. lower alkyl or taken together with the adjacent nitrogen atom represent a saturated 5 - 6 membered heterocyclic ring which may contain a further heteroatom, R7 and R8 represent hydrogen or, taken together, a 1,3-butadienylene radical forming a benzo system fused with the pyridazine ring, for example N-2,5-dimethyl-1H-pyrrol-1-yl)- 6-morpholino-3-pyridazineamine or N-(2,5-dimethyl-1H-pyrrol- 1-yl)-4-(4-hydroxypiperidino)-1-phthalazineamine, and their pharmaceutically acceptable salts are made e.g. by contacting a hydrazino derivate of the formula (II), wherein the substituents have the same meaning as above or an acid addition salt thereof with a dicarbonyl compound of the formula (III), wherein the substituents have the same meaning as above, or a functional derivative thereof in the presence of an acid catalyst at a temperature between 15°C and 120°C. The new compounds can be used as antihypertensive agents.

  在式 (I) 的 6 位具有另一个氨基取代基的新型 N-吡咯烷-3-哒嗪胺、 其中 R、R1、R2 和 R3 为氢或低级烷基，R4 如为氢或低级烷基，R5 和 R6 如为R5和R6是低级烷基，或与相邻的氮原子一起代表一个饱和的 5 - 6 个成员的杂环，该杂环可能含有另一个杂原子，R7和R8代表氢，或与 1、例如 N-2,5-二甲基-1H-吡咯-1-基）-6-吗啉基-3-哒嗪胺或 N-(2,5-二甲基-1H-吡咯-1-基)-4-(4-羟基哌啶基)-1-酞嗪胺及其药学上可接受的盐。例如，将式（II）的肼基衍生物（其中取代基的含义同上）或其酸加成盐与式 （III）的二羰基化合物（其中取代基的含义同上）或其官能衍生物在酸催化剂存在下于 15°C 至 120°C 的温度下接触。 新化合物可用作降压药。
• Szilagyi; Kasztreiner; Matyus, European Journal of Medicinal Chemistry, 1984, vol. 19, # 2, p. 111 - 117
  作者：Szilagyi、Kasztreiner、Matyus、et al.

  DOI：——

  日期：——
• Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines
  作者：Elvio Bellasio、Ambrogio Campi、Nunzio Di Mola、Emiliana Baldoli

  DOI：10.1021/jm00374a024

  日期：1984.8

  The hypothesis that the side effects of hydralazine, such as mutagenicity and lupus erythematosus like syndrome, might be due to the NHNH2 group prompted us to incorporate part of this moiety into a pyrrole ring. Therefore, we prepared a series of N-1H-pyrrol-1-yl-3-pyridazinamines and a limited number of N-1H-pyrrol-1-yl-1-phthalazinamines by reaction of 3-hydrazinopyridazines and 1-hydrazinophthalazines with gamma-diketones. Most of these compounds, especially in the pyridazine series, showed moderate to strong antihypertensive activity in spontaneously hypertensive rats. The decrease in blood pressure generally had a slow onset after either oral or intravenous administration. N-(2,5-Dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride (30) (MDL 899) showed no mutagenic activity in several tests and is now in clinical trials in patients.
• US4247551A
  申请人：——

  公开号：US4247551A

  公开（公告）日：1981-01-27